Abstract

ObjectivesThe objective of this research was to examine the association between total flavonoid intake and flavonoid sub-classes and CVD mortality among a nationally representative sample of US adults aged 40+ years at baseline and free of CVD. MethodsA nationally representative sample of adults from the NHANES III data (1988–1994; n = 7900; age > = 40 years) were matched with mortality data reported by the National Death Index through 2015 to examine associations between estimated usual intakes of total flavonoid intake and flavonoid sub-classes and CVD mortality. Cox Proportional Hazards regression models were constructed to estimate hazard ratios and 95% confidence intervals for CVD mortality. Up to four 24-hour recalls were used to estimate total flavonoid intake and flavonoid sub-class intake for participants at baseline. ResultsDuring a median follow-up of 17.9 years, there were 4245 death; 1629 CVD deaths (767 males, 862 females) documented. Mean flavonoid intake was 247.7 mg/day for males and 216 mg/day for males. We did not observe an inverse association between total flavonoid intake and CVD mortality for males (HR: 0.95, 95% CI 0.87, 1.03) or females (HR: 1.03, 95% CI 0.93, 1.14), after adjustments for demographic, lifestyle, clinical and dietary quality variables. We also did not find significant associations between intake of flavonoid sub-classes and CVD mortality. However, for males only, intake of flavanones was inversely associated with CVD mortality after adjustments for demographic variables, lifestyle, clinical variables and diet quality (HR: 0.93, 95% CI 0.87, 0.99, p-value < 0.04). ConclusionsIn this nationally representative study, with detailed information on flavonoid intake and CVD mortality data, we did not find an inverse association between total flavonoid intake and most flavonoid sub-classes and CVD mortality for adults aged 40+ years at baseline; however our findings do indicate a marginally significant inverse association between flavanone intake and CVD mortality for males only, after controlling for confounders. Funding SourcesNo funding sources to declare.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call